secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mersana Therapeutics, Inc. (—)
CIK:        0001442836
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001104659-24-028715
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mersana Therapeutics enters $100M ATM sales agreement with TD Cowen
-------------------------------------------------------------------

- Company entered Sales Agreement to sell up to $100M of common stock at-the-market through TD Cowen.
- TD Cowen will receive up to 3.0% commission per share sold; no minimum obligation to sell shares.
- Offering is under existing S-3 registration statement that became effective February 28, 2024.
- Company may suspend or terminate the offering at any time upon notice to TD Cowen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1442836/000110465924028715/0001104659-24-028715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1442836/000110465924028715/tm247340d5_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-028715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer